Information Provided By:
Fly News Breaks for March 4, 2016
BIOS
Mar 4, 2016 | 08:52 EDT
Stephens analyst Dana Hambly said he is starting to regain confidence in the leadership of BioScrip after the company's second straight quarter of above consensus results. The company's balance sheet is "still scary" due to the company's leverage, but that is an improvement from its prior "terrifying" level, Hambly tells investors. The company has a "real opportunity" for double-digit profitability growth, said the analyst, who keeps an Overweight rating and $3.25 price target on BioScrip shares.
News For BIOS From the Last 2 Days
There are no results for your query BIOS